

PH1.43

SULFONAMIDES

AND

COTRIMOXAZOLE

Compiled By –

Dr. ARPIT VERMA

MBBS, MD, CCEBDM (Diabetology)

Associate Professor (Pharmacology)
Uttar Pradesh University of Medical

Saifai, Etawah (U.P.)- 206130



Scienc

ANTIMETABOLITES/ ANTIFOLATE ANTIBIOTICS

- These drugs are able to interfere with the role of an endogenous compound e.g folic acid, in the cellular metabolism.

Examples:

- Dapsone*
- Para-amino salicylic acid*
- Sulfonamides*
- Pyrimethamine*
- Proguanil*
- Methotrexate*
- Trimethoprim*

SULPHONAMIDES

- ❑ These are first antimicrobial agents used in treatment of bacterial infections.
- ❑ Derivative of sulphanilide and are synthetic congener of PABA.
- ❑ Due to emergence of resistance and availability of better drugs, sulfonamides are less frequently used nowadays.
- ❑ These drugs are ***bacteriostatic agents*** and act by ***inhibiting dihydropteroate synthase (DHPS)/ folate acid synthase competitively, involved in folic acid synthesis.***

MECHANISM OF ACTION

- Bacteria can synthesize folic acid via PABA-very essential for purines and nucleic acid synthesis.
- **Drugs inhibiting folic acid synthesis:** Folic acid synthase (dihydropteroate synthase) results in the formation of folic acid by incorporation of PABA.
- *Sulfonamides, dapsons and paraaminosalicylic acid (PAS)* are structural analogues of paraaminobenzoic acid (PABA).
- These drugs act as **competitive inhibitors** of folic acid synthase.

- **Dihydrofolate reductase (DHFRase) inhibitors:**
DHFRase is the enzyme responsible for conversion of dihydrofolic acid to tetrahydrofolic acid.
- Latter is the active form required for the transfer of one carbon units.
- Drugs inhibiting this enzyme are *pyrimethamine, methotrexate, proguanil and trimethoprim.*

PABA + Glutamate + Pteridine

Folic acid synthase

Dihydro Folic Acid

DHFRase

Tetrahydro Folic Acid

DNA

Sulfonamides

PAS

Dapsone

Trimethoprim

Pyrimethamine

Proguanil

Methotrexate

(-)

(-)

- ❑ The selective toxicity to bacteria is due to the reason that mammalian cells do not synthesize folic acid and utilize preformed folic acid in the diet.
- ❑ Sulfonamides are **not effective in the presence of pus** because it contains large amount of PABA.

PHARMACOKINETICS

- ❑ Rapidly absorbed from GIT
- ❑ Widely distributed in body tissues
- ❑ Can enter pleural, peritoneal, synovial, ocular and other body tissues
- ❑ Cross BBB and Placenta.
- ❑ Binds to plasma protein albumin.
- ❑ The solubility of sulfonamides decrease in the acidic urine, which may result in precipitation of the drug causing **crystalluria**.
- ❑ Risk is **minimum with** soluble drugs like **sulfisoxazole**.

- **Sulfadoxine** is **longest acting** whereas **sulfacytine** is **shortest** acting sulfonamide.
- These drugs undergo hepatic metabolism by **ACETYLATION**
- Drugs undergoing acetylation are **SHIP**: Sulfonamides including *dapsone, Hydralazine, Isoniazid and Procainamide*) and can cause SLE.
- Excreted via kidney, so dose to be reduced in renal failure

CLASSIFICATION

- **Systemic acting oral agents**
- *Short acting: (4-8 hrs)* Sulfisoxazole, Sulfacytine, sulfadiazine
- *Intermediate acting: (8-12 hrs)* Sulfamethoxazole, sulfamoxazole
- *Long acting: (7 days)* Sulfadoxine, sulfamethopyrazine
- **For use in GIT as orally nonabsorbable agents:** Sulfasalazine, olsalazine, balsalazine
- **For topical use:** Sulfacetamide, silver sulfadiazine, mafenide

ANTIBACTERIAL SPECTRUM

- Active against gram negative bacteria- Ecoli, salmonella, proteus, Vibrio cholera.
- Some gram negative bacteria- Staph, Gonococci, Meningococci, Pneumococci
- Others- Toxoplasma gondii, P. falciparum, Chlamydia

MECHANISM OF RESISTANCE

- Mutation in the enzyme folate synthase
- Efflux of drug
- Low permeability of drug
- Increase production of PABA via alternate pathway

CLINICAL USES

- **UTI:** Sulfisoxazole has the most rapid oral absorption and most water soluble sulphonamide, hence it causes less crystalluria.
- It is used for acute cystitis.
- **Otitis media-** Sulfisoxazole can also be used in otitis media

- **Ulcerative colitis and Enteritis:** Sulfasalazine and olsalazine are used for the treatment of ulcerative colitis.
- Its active component for anti inflammatory activity is 5-ASA.

- **Nocardiosis**-Sulfadiazine can be used for nocardiosis
- **Trachoma and Chancroid**- Sulphonamides can be used as an alternative to azithromycin and tetracycline

TOXOPLASMOSIS

- **Sulfadiazine and Pyrimethamine** combination can be used for the treatment of toxoplasmosis.
- Combination used for 6 months.
- Pt should receive 2L of fluid daily to prevent crystalluria.
- Since antifolates are contraindicated in pregnancy, **Spiramycin** is DOC for toxoplasmosis in pregnancy.

PNEUMOCYSTIS JIROVECI INFECTION PROPHYLAXIS

- Combination of **Sulfadiazine and pyrimethamine** is also used for prophylaxis of *Pneumocystis jiroveci* pneumonia in AIDS patients.

Other drugs:

- Dapsone
- Pentamidine
- Atovaquone

CQ RESISTANT MALARIA

- **Sulfadoxine** (longest acting sulfonamide) **plus pyrimethamine and Artesunate (ACT)** is used for treatment of CQ resistant malaria and mefloquine resistant malaria.

WHO RECOMMENDED ARTESUNATE COMBINATION THERAPY (ACT)

- Artemether-Lumefantrine
- Artesunate-Amodiaquine
- Artesunate-Mefloquine
- **Artesunate-Sulfadoxine-Pyrimethamine**
- Dihydroartemisinin-Piperaquine

TOPICAL AGENTS

- Mafenide, sulfacetamide, Silver sulfadiazine are used as topical sulphonamides.
- Silver sulfadiazine > Mafenide are used in burn patients to prevent infection.
- Silver sulfadiazine has antifungal effect as well, hence used in fungal keratomycosis.
- Sulfacetamide is used for ocular infections as eyedrops.

ADVERSE EFFECTS

- **Skin rash and SJS** due to hypersensitivity is the most common adverse effect.
- **BM Suppression:** These can also cause **granulocytopenia, thrombocytopenia and aplastic anemia** (more common in HIV infected patients).
- **Hemolysis:** Sulfonamides can cause **acute hemolysis** in patients with **G-6 PD deficiency**.

- **Crystalluria:** These can precipitate in the urine at acidic pH and may result in **crystalluria and hematuria**. (mostly with older sulphonamides).
- It can be prevented by taking large amount of water and alkalization of urine by sodium bicarbonate.

- **GIT:** Nausea, vomiting diarrhea.
- **Kernicterus:** These can displace bilirubin from plasma protein binding sites and may result in **kernicterus** in the new born (if given in third trimester of pregnancy) as it crosses BBB and deposited in basal ganglia.
- Mafenide is toxic of all three topical agents. It can cause allergy, pain on application and metabolic acidosis (by inhibiting carbonic anhydrase)

ADVERSE EFFECTS

(Mnemonics)

- **B**- Bone marrow suppression
- **I**- Insoluble in urine (Crystalluria)
- **K**- Kernicterus in neonates
- **A**- AIP, Agranulocytosis
- **S**- SJS, Rash
- **H**- Hemolysis

STEVENS JOHNSON SYNDROME



TRIMETHOPRIM

- It is a **bacteriostatic antimetabolite** that inhibits dihydrofolate reductase.
- It is highly selective for bacterial DHFR and doesn't effect human folate metabolism.
- It attains **high concentrations in the prostate and vaginal fluids.**
- For most of the indications, it is combined with sulfonamides; however it can be used **alone in prostatitis and UTI.**
- **Chances of resistance develops if used alone, hence used in FDC.**

- It can cause **megaloblastic anemia** (can be ameliorated by folic acid), leucopenia and pancytopenia.
- It can also result in **hyperkalemia** (due to amiloride like action i.e., inhibition of epithelial Na⁺ channels in CD).

Note:

- Other DHFRase inhibitors are pyrimethamine, methotrexate, proguanil and pentamidine.
- All DHFRase inhibitors can cause **megaloblastic anemia**.

COTRIMOXAZOLE

- Cotrimoxazole is a fixed dose combination of **sulfamethoxazole and trimethoprim** in a ratio of **5:1**. because of high volume of distribution of trimethoprim than sulphonamide.
- Both drugs have similar half life and the combination is **bactericidal** to most pathogens.
- The bactericidal activity is due to **sequential blockade** at two steps in the DNA synthesis (sulfamethoxazole inhibits folate synthase and trimethoprim inhibits DHFRase).

- This is a **synergistic combination**.
- Due to different bioavailability (more for sulfamethoxazole), plasma concentration of the two drugs attained is **20:1**.
- **Chances of resistance develops if trimethoprim or sulphonamide used alone, hence used in FDC.**

COTRIMOXAZOLE DOSAGE

Sulfamethoxazole (mg)	Trimethoprim 1/5 th dose (mg)	Preparations
100	20	Pediatric tablet
200	40	Oral suspension
400	80	Oral(single strength) , i.v.
800	160	Oral tablet double strength (DS), i.m.

USES

- **UTI:** caused by Ecoli, proteus and Enterobacter
Acute Uncomplicated and chronic recurrent UTI.
- **Prostatitis**
- **URTIs and LRTIs**-middle ear and sinus infections caused by hemophilus and moraxella.
- **Bacterial gastroenteritis and dysentery** – caused by , E.coli, salmonella, shigella, travelers diarrhea due to V. cholera
- **Typhoid fever**

- **Pneumonia by Pneumocystis jiroveci infection**
- **Chancroid**
- **MRSA**
- **Whipples disease**
- **Melioidosis**
- **Nocardiosis (DOC)and brucellosis**
- **It is the drug of choice for pneumocystis jiroveci, nocardiosis, burkholderia cepacia, isosporiasis, cyclosporiasis, sarcocystosis and cystitis.**

ADVERSE EFFECTS

- Adverse effects are similar to sulfonamides and trimethoprim.
- Permanent impairment in renal function can occur in preexisting renal disease.
- **Contraindicated in pregnancy** as it causes neonatal hemolysis and **methemoglobinemia**.

Note: Nowadays, Resistance is common due to **plasmid mediated mutation**.

DRUG INTERACTION

- Sulphonamides increases toxicity of phenytoin, tolbutamide and warfarin, aspirin due to displacement from plasma protein binding sites.
- Sulphonamides causes methotrexate toxicity via inhibiting its renal toxicity

THANKS